Nevirapine

Specifications

129618-40-2CAS Number

603-345-0EC Number

2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-oneIUPAC Name

C15H14N4OChemical Formula

266.3 g/molMolecular Weight

nevirapine; 129618-40-2; Viramune; BI-RG-587; Nevirapine anhydrous; Viramune XR; BIRG 0587; Nevirapine, anhydrous; Nevirapine teva; BIRG587; BIRG-0587; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; Nevirapina; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; DTXSID7031797; 99DK7FVK1H; Nevirapinum anhydrous; NSC-641530; BIRG0587; CHEBI:63613; NSC641530; 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; DTXCID9010787; 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one; BI RG 587; nevirapinum; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo(9.4.0.0^(3,8))pentadeca-1(15),3,5,7,11,13-hexaen-10-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo(9.4.0.03,8)pentadeca-1(11),3,5,7,12,14-hexaen-10-one; 6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-; Hemihydrate, Nevirapine; RefChem:853798; J05AG01; NEVIRAPINE TABLETS FOR ORAL SUSPENSION; 603-345-0; 4-amino-1-((2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl)pyrimidin-2-one; NVP; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; MFCD00866928; BIRG-587; CHEMBL57; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE; NEV; MLS000084585; NCGC00065890-02; SMR000048458; S1742; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one; BI-RG 587; Viramune(TM); Viramune (TN); CAS-129618-40-2; HSDB 7164; Nevirapine & CD4-IgG; Nevirapine & PRO 140; UNII-99DK7FVK1H; NSC 641530; Nevirapine (JAN/USP/INN); Nevirapine); 11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one; BIRG 587; Nevirapine RS; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Viramune IR; 1vrt; 2hny; Nevirapine [USAN:USP:INN:BAN]; BI-RG-587 & CD4-IgG; Nevirapine (Standard); Nevirapine (Viramune); NEVIRAPINE [MI]; Opera_ID_934; NEVIRAPINE [INN]; NEVIRAPINE [JAN]; NEVIRAPINE [HSDB]; NEVIRAPINE [USAN]; NEVIRAPINE [VANDF]; Epitope ID:231711; Nevirapine (anhydrous) CRS; NEVIRAPINE [MART.]; SCHEMBL3318; NEVIRAPINE [WHO-DD]; MLS000759409; MLS001055309; MLS001201730; MLS001424058; MLS006011423; BIDD:GT0326; NEVIRAPINE [EMA EPAR]; BDBM1434; orb1308075; orb3141273; NEVIRAPINE [ORANGE BOOK]; SCHEMBL29393780; SCHEMBL29614675; SCHEMBL30267890; GTPL12676; NEVIRAPINE [EP MONOGRAPH]; NEVIRAPINE [USP IMPURITY]; HMS2051J09; HMS2231O23; HMS3264D21; HMS3371E03; HMS3393J09; HMS3655I08; HMS3715B10; HMS5079D22; NEVIRAPINE [USP MONOGRAPH]; Pharmakon1600-01503842; ALBB-027264; BSB41895; MSK10168; Tox21 110982; Tox21_110982; Tox21_200770; AC-643; AC1280; BBL010768; EBC-11254; HY-10570R; NSC759902; STK580320; NEVIRAPINE ANHYDROUS [USP-RS]; NEVIRAPINE ANHYDROUS [WHO-IP]; AKOS005504351; Nevirapine for peak identification CRS; Tox21_110982_1; AB07544; CCG-100939; DB00238; KS-5019; NC00189; NN15304; NSC-759902; NCGC00065890-03; NCGC00065890-04; NCGC00065890-05; NCGC00065890-07; NCGC00065890-14; NCGC00258324-01; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); HY-10570; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; Nevirapine 100 microg/mL in Acetonitrile; SY009679; BI-RG 587;NSC 641530;NVP; DB-041930; N0922; NEVIRAPINUM ANHYDROUS [WHO-IP LATIN]; NS00004959; SW197569-2; C07263; D00435; EN300-119500; AB00393001-13; AB00393001-15; AB00393001_16; AB00393001_17; F358078; Q263713; BRD-K15502390-001-19-1; BRD-K15502390-001-20-9; F2173-0607; Z1521553473; Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard; Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard; Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one; 6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e][1,4]diazepin-6-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0,3,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one; Nevirapina, anhidraSynonyms